Most practices can see how they're performing; their dashboards show plenty of metrics. But nobody's diagnosing why dormant revenue assets sit uncaptured in the PMS, quantifying what they represent in recoverable revenue, and documenting it in an institutional-grade format that holds up in the data room.

That's the gap DRAI was built around. We go into the PMS, identify where revenue is leaking and why, and produce a forensic diagnostic that quantifies it and maps the recovery path. As an independent third party, we have no stake in the outcome, hence giving the report its weight and credibility in the room.

Acquirers, owners, and the advisors around them retain us to establish the revenue a target is not capturing from the patients it already holds, and to document it to the standard a deal team requires, so that an acquirer underwrites and plans on that figure and a seller either captures it before listing or documents it so that the gaps/weaknesses cannot be discounted at the table.

The dental roll-up was built on multiple expansion. You bought at 5x, exited at 12x, and the spread was the return, which meant operational variance at each tuck-in didn't have to be amazing. That spread is gone. PE firms now hold dental assets six years and longer, and over the past two years more than 40 DSOs went to market and fewer than 10 closed.

When the multiple no longer carries the return, the return has to come from running the practice better than the seller did. And you cannot capture operational alpha you never documented.

That's the thesis behind DRAI and its Operational QoE.

The Operational QoE gathers the granular operational detail that your existing diligence process misses to capture in the small post-LOI window. DRAI does this by going into the practice management system and quantifying recoverable revenue across five categories, in a transaction-grade format built for the investment committee, the lender's credit desk, and the counterparty's diligence team, and that your operations team can execute from.

Our role in a transaction is to close the information asymmetry between what a practice's financials show and what its patient base can actually produce, and to hand that edge to the party that retained us.

DRAI is retained by acquirers, sellers, groups reviewing the locations they own, and the advisors and lenders around them, on transactions and reviews priced on EBITDA, by one side of a transaction only. An engagement needs 24 months of practice management history and four weeks from complete data to delivery. We document and quantify; you and your counsel structure and negotiate with it.

Every figure in the report shows its derivation and reconciles against every other figure, so your own advisors can check the work. Where a figure has to hold up to the other side of your transaction, we revise it to that standard, once, at no additional fee. Fees are fixed per engagement and never move with the number. Findings go to the party who commissioned them and nobody else.

We take on two to three groups a quarter. Acquirers with a pipeline engage us at LOI. If we are at capacity when you reach us, we scope and paper the engagement immediately and hold your start date.

On an acquisition the work runs after LOI and before close, on the access the LOI already grants, and is delivered before the financial QoE closes. The ideal moment to engage is at or shortly before LOI, so the full diligence window is available once the seller's data is released. Sellers use it 12 to 24 months before an expected LOI, when recovery still lands in the trailing earnings a buyer prices, or inside the last 90 days before signing, when documentation anchors the structure instead. Groups run it on the locations they already own at any point, including alongside live acquisitions.

Typically, the growth plan is written before the operational picture actually exists, which means the targets in it are assumptions about a practice nobody has measured yet, so the integration team inherits whatever diligence did not find, and by the time operations catches up, the months that compound most have gone to discovery rather than execution. The Operational QoE is delivered inside the diligence window, before close, so the plan is written from measured figures, the opportunity is already located and sized, and the team starts capturing in month one with the accuracy the model assumed and the speed the hold period needs.

Behind the report is a method built over the past year for dental practice management data, with AI carrying the data-heavy work. Each engagement adds its pre-close figures and post-close recoveries to a benchmark no group and no analytics vendor is positioned to build, because neither sees the practice on both sides of the transaction.

Every acquirer we have spoken with describes the same gap. Someone on the team could go through a practice's reports and find the opportunity; nobody has a method for turning what they find into a document a sponsor, a lender, or a board will accept inside the diligence window. The Operational QoE is that method: the operational read, converted into the figures the finance side prices on.

What we built, and run on every engagement:

• One data request for every practice management system. Dentrix, Open Dental, Eaglesoft, Curve, and the rest each report the same things in different formats and under different names. We translate every export into one set of definitions, so a Dentrix group and an Open Dental practice are measured on the same terms and can be compared.
• Five categories with fixed definitions. What counts as a lapsed patient, an unscheduled plan, a lost appointment, provider variance, and a retained new patient is defined once and applied the same way to every location, on every engagement. Every figure ties back to the specific report it came from, so your own advisors can re-run it.
• Conversion on your numbers, not industry averages. Recoverable production runs through the practice's own write-offs and collection rate to cash, then through your own cost stack to EBITDA, then to value at your multiple. Along the way we check that the practice has the chair time and provider capacity to deliver the production, so nothing is counted that the building cannot produce.
• A report with a section for every reader. Executive summary for the investment committee, category pages for the operations team, the conversion for the CFO, the structural findings for the lender, the appendices for whoever wants to check. Whether the report is being used to approve, to execute, to underwrite, or to show a partner what was found, each reader finds their part written for them. Roughly thirty pages, four weeks from complete data, on every engagement.
• A record that compounds with every engagement. At 6, 12, and 24 months the figures quantified before close are compared against what was recovered after it, practice by practice, category by category. Over time that becomes something no group can build for itself: a benchmark of what each kind of opportunity is actually worth, which drivers are fixable and which are not, and how far a pre-close figure lands from the post-close result. A group sees its own deals, a few a year. An analytics vendor sees the practice after it is bought, never before. We see the practice on both sides of the transaction, across every group we work with, and every engagement makes the next figure more defensible than the last. That is the part of this work that cannot be hired for or built internally, because it only exists at volume, across firms, over years.

We spent the past year building this before taking a client. AI carries the data-heavy work inside it: reading the exports, rebuilding the patient base's visit and treatment pattern by cohort from the summary reports, and checking every figure against every other so the report reconciles in every section. That is how a six-location tuck-in gets the same depth on every location inside four weeks.

Recently I posted the “2026 Dental M&A Thesis”, where I discussed why 75% of DSOs that went to market failed to close, and how the era of buying cheap and selling high on multiple expansion is over. It resonated with a lot of M&A teams, brokers, and dental operators, because everyone is already feeling the problem. Simply put, returns now have to come from how the practice is actually run.

As a result, the obvious question today which nobody has a clean answer to, is this:

If returns now come from how a practice is run, how do you actually measure that, in dollars, before you buy it or sell it?

That question is what DRAI exists to answer. It's not about what the seller says, or what the financials imply, but what is actually true.

We measure it, and we coined it the Operational Quality of Earnings.

The Operational QoE answers two questions a Financial QoE was never built to touch: how much more could this practice earn from the patients it already has, and will the earnings you are paying for still be there in two, three, five years?

Knowing the answers is not a “nice to have”. It decides real value on both sides of the table.

General awareness is not alpha. Specificity is.

For a buyer, not knowing the specifics costs you in two areas.

The first is price. You pay a multiple of EBITDA, so the number that actually matters most is not what the practice booked in the last few years but the EBITDA that it can sustainably produce going forward. Almost every practice has recoverable production sitting in its own patient base that never reaches the financials, which means the realistic, achievable earnings are higher than the trailing numbers suggest.

What buyers do today is price off the trailing financials, confirm them with a financial QoE, and make a vague assumption that there is probably some upside to capture once they own it. But that assumption is just that, an assumption. There is no real number attached to it, so it cannot go into the model, the bid, or the plan in any concrete way. It sits in the back of your mind as “this should get better,” and the actual work of finding out how much better only starts after you have already bought it.

That's why we put a real number on it before you price. How much upside is realistically in this practice, where it sits, what is causing it, and what it would take to capture, modeled conservatively and broken out by category and location, in a form your investment committee will accept. That is the whole difference. You price and forecast the way you always have, except the upside in your model is now a measured figure you can stand behind instead of a hope, so you underwrite the real return with conviction, pay the right price rather than guess at it, and structure the deal around what is actually there. In a market where the easy multiple-expansion returns are gone, that is the edge, and the fee is a rounding error against the size of the deal.

The second cost is time. Here's the thing, buyers know that upside potential exists. Of course they know opportunity is there. But knowing “there's likely room to improve recall and unscheduled treatment conversions” is not something you can price, underwrite, or hand to your team as a plan, while a number, broken out by category, location, and root cause, is. Without that, the work of turning assumptions into a real plan only starts after the wire clears, when your integration team pulls the reports, finds the gaps, builds the plan, and finally starts executing. That's usually many months in because they are doing it reactively while also absorbing staffing, systems, and everything else a new practice brings.

In a leveraged hold, every month of that delay is expensive. Earnings recovered in month three compound across almost the entire hold and sit in the trailing numbers you eventually sell on, while the same earnings recovered in month fifteen compound across far less and may never reach the exit multiple at all. The distance between executing on day one and discovering over year one is a real difference in IRR, on upside that was always there.

For a seller, the same gap in specifics costs you twice too.

Any recoverable production you never captured is revenue the practice could have earned and simply did not, so it never showed up in your numbers. And because a practice sells for a multiple of its EBITDA, every dollar of EBITDA missing from those numbers is several dollars off your final price. Capture even $200,000 of recoverable production into your trailing EBITDA before you list, and at a normal multiple that is well over $1 million of additional sale price. Since a practice's overhead is largely fixed, almost all of that recovered revenue falls to the bottom line. But if you leave the recoverable revenue unknown, it'll remain as untapped potential, a missed opportunity.

Second, the gaps you do not document become the buyer's leverage, which is why you want to control the narrative going in. In diligence, an operational weakness the buyer finds that you cannot strongly explain gets treated as risk which is discounted far beyond the risk it actually represents, because an unexplained problem always looks bigger than a measured one. So if you proactively walk in with that same gap already quantified and framed as a fixable operational issue with a known dollar value, it gets priced for what it is instead of used to re-trade you down while you scramble to respond.

That is the problem on both sides. The Operational QoE is the document that closes it.

What the Operational QoE actually is

It finds the value a practice is leaving on the table and the risks hiding inside its earnings, measured both in dollars from the practice's own data, and hands over the exact roadmap of what to do about it.

It's independent, evidence-based, and built to stand up in a data room alongside the financial QoE. We only do the measuring, not the fixing, and that's deliberate. A number only carries weight in a deal room if the firm producing it has nothing to gain from the answer. Staying independent is what makes the number trusted by both sides. The revenue recovery work itself goes to the client's own team.

The five categories we look at, and why these five

• Lapsed recall. Patients who completed treatment, were due back, and fell off the schedule. Usually the single largest pool because recall is the recurring revenue engine of a practice and it leaks slowly enough that nobody notices the size of it.
• Unscheduled treatment. Cases the dentist diagnosed and the patient accepted, that never got booked into a chair. The highest-probability untapped value in the building because the patient already said yes.
• No-shows and cancellations. Chair time that was sold and then lost, with no system to recover it.
• Provider variance. Two clinicians working the same patient flow and the same schedule, producing very different numbers. It shows where capacity is being left on the table and whether production is replicable or quietly dependent on one person.
• New patient retention. Patients a practice paid $300 to $500 to acquire, seen once and never brought back. The difference between growth that compounds and a treadmill that just looks like growth.

These five matter for a reason: each is large enough on its own to move a deal, each sits in the practice's own data so it can be proven rather than asserted, and each traces to a specific root cause a new owner can actually fix. Since the capacity to deliver this production already exists, almost all of it converts straight to EBITDA once captured, which is what makes it move valuation at the multiple. None of it is owed to the practice, it's production the practice is capable of and simply is not capturing, invisible on a financial statement because none of it ever generated a billing event.

If it's so obvious, why is the value still untapped?

None of these five categories are a secret, and any operator reading this already knows practices leak revenue in those areas. That's exactly the point: the problem was never that the categories are hidden, it's that in the context of M&A, for practices actually on the table when someone is about to buy it or sell it, nobody has measured the actual untapped revenue, where it sits and what is causing each gap to a standard anyone can act on.

There are a handful of structural reasons for why this has been the case, deal after deal.

• Bandwidth. In a live transaction the deal team is consumed by the deal, and after close the integration team is absorbing staffing, systems, and several practices at once. Nobody has the room to go through one practice's operations in the kind of detail this takes, and pin down exactly where the money is leaking, while the clock is running.
• Complacency. When a practice or a group is growing or simply doing fine, the leakage never feels urgent enough to dig into. Good enough wins, and the true size of what is being left behind stays invisible.
• It's nobody's actual job, because it falls in the gap between two skill sets. The analysts running a deal know finance, not the true day-to-day reality of how a dental practice actually runs. The operators who know that reality cannot usually translate it into what it is worth in a transaction. The whole job is the bridge between the two, reading the operation and converting it into dollars on the valuation, and that is a different discipline from doing deals, practising dentistry, or moving listings. It is the only one we do.

Also, you cannot credibly mark your own homework. A number the seller produces or the buyer's own team produces carries little weight in a deal room, because everyone there knows who it benefits. The figure has to come from someone with nothing to gain from the answer.

Not to mention, the tools they already have were built for something else entirely. A practice management system like Dentrix or Open Dental stores the data and prints reports, it does not interpret them for a transaction. And analytics or intelligence platforms like Dental Intelligence or Jarvis are an ongoing operating tool a practice runs on itself, day to day, to watch its own numbers. Both are genuinely useful, but neither is built for a deal room nor hands a buyer or a seller an independent, normalized, benchmarked, root-caused dollar figure of recoverable production and earnings risk with a firm's name standing behind it.

A dashboard helps you run a practice you already own, but an Operational QoE tells you a practice's true potential and what is really inside it at the moment it changes hands. That is the gap, and it is the whole reason we exist. We are not another vendor handing you a dashboard. We are the independent partner that does the simple, unglamorous, neglected work, at depth, on the clock, as an extension of your side of the deal, at every stage of the journey.

What the gaps usually look like

They are rarely small, and they are rarely where an owner expects. A group can be running full schedules and growing collections while several thousand patients sit outside recall, because the person who ran the recall process left and the process left with them. Accepted treatment accumulates in the ledger for years, in six figures on a mid-sized group, because the practice did the hard part, the diagnosis and the patient's yes, and never put the work in a chair. No-shows run at double the rate in some locations of the same group compared to others, for reasons nobody has looked into. And new patients that cost several hundred dollars each to acquire get seen once and never brought back, while the practice keeps spending to replace them.

The point is not the range. It is that none of it appears anywhere in the financials, because none of it ever generated a charge, so the only way to know the size of it in a particular practice is to measure that practice. That is what the engagement produces: the figure for the group in front of you, not an industry average.

Operational QoE: for buyers

For a buyer acquiring and expanding a group, an Acquisition Diligence Operational QoE does two jobs.

The first is quantifying the upside. We measure the recoverable production sitting in the practice, where it sits and what it's worth so that you go into the deal knowing what the practice can sustainably produce long-term, and why.

It is a specific, located, root-caused figure for this practice, with conservative conversion assumptions you can defend to a committee. It is quantified, recoverable upside to that same EBITDA, which nobody else has measured, so it tells you the real return the deal can produce before you commit. Broken out by category and location, that lets you underwrite with conviction, pay the right price rather than guess at it, and judge whether the deal clears your return bar at all. A corporate development lead at one of the largest DSOs recently told me that knowing the recoverable revenue before close would change what they are willing to pay for a practice. And the day you close, your team runs a recovery plan that is already built and prioritized instead of spending months working out where the upside is in this specific practice. Since you start capturing quicker than you normally would have, that same recovery lifts the IRR across the hold.

The second job is the durability of those earnings. A financial QoE confirms what the practice earned, but not whether the operations producing those earnings are healthy. Standard diligence handles the obvious risks, like a selling dentist's transition, through deal structure. What it does not quantify is the trajectory underneath the revenue line: whether the active patient base is growing or shrinking while fee increases prop up the top line, and whether new-patient growth is being retained or churning straight back out. A practice can look stable on the P&L while the base that feeds it hollows out, and for a buyer paying a multiple of today's EBITDA, that is the difference between earnings that compound and earnings that fade. It lives in the patient data, not the financials. A healthcare banker who has financed hundreds of these deals put it in perspective for me: he underwrites seven-figure loans on practices' financials and has never once seen an operational read like this in a deal. The people with the most capital at risk are working off half the picture, which is exactly the edge for the ones who stop doing that.

The value compounds at scale. On a single acquisition the edge can look modest, a slightly sharper price, some upside reached a few months sooner. But a platform is not buying one practice, it's buying twenty, forty, eighty a year, and that edge multiplies across every one of them. A serious acquirer was always going to create value in the practices it buys, so the difference is not whether value gets created, it is how much of it actually gets captured and how fast you get there. Walking in with a measured number means you capture more of what is genuinely in the practice instead of leaving part of it sitting there, you start on day one rather than months later once your team has finally worked the practice out for itself, and you do it with far less friction than reconstructing it reactively after close. Even an extra $100,000 per deal that you would otherwise have left uncaptured or only reached too late, across 40 acquisitions, is $4 million of EBITDA you would not have had, and at an 8x exit roughly $32 million of enterprise value, on top of the returns you were always going to make anyway. And because earnings recovered early compound across almost the whole hold, getting to them on day one instead of a year in lifts the IRR on every deal you do. That same read protects you on the deals where the earnings were quietly fading or the growth was a treadmill, the ones you reprice or walk away from before they ever reach your portfolio. One sharp read is a good deal. The same read on every deal, every year, is the difference between a platform that compounds and one that quietly wonders why its returns keep lagging its model.

Operational QoE: for sellers

You have two moments to use this, and they do different jobs.

With real runway before a sale, a Pre-Listing Operational QoE measures the recoverable revenue and gives you the roadmap to capture it into EBITDA before you go to market. The logic is simple: lift your actual EBITDA before you list, and because the price is a multiple of that EBITDA, you sell for more, on numbers you genuinely improved, while pocketing the extra profit in the months before the sale. A dental exit-planning specialist ran the math on a call: find an owner $300,000 of recoverable EBITDA, and at a 7x multiple once captured you have added $2.1 million to the sale price.

When the listing is close, a Going to Market Operational QoE hands you control of the narrative so the buyer's diligence cannot drive it. Normally the buyer finds the gaps and uses each one to re-trade you down. Walk in with the operational picture already documented and there is nothing left to discover and weaponize, because a known gap gets priced fairly while an unknown one gets discounted far past its real size. It also strengthens the earn-out terms which usually hang on future performance neither side fully controls, which is why so many never pay out. So if you build it on dormant assets that already exist, the accepted treatment and lapsed patients sitting on the books, you get paid for value you already created once it's converted. As a broker with twenty-five years on the sell side put it, owners and their advisors usually do not know how to find or structure this themselves. That is the gap we fill, working alongside the brokers, advisors, and attorneys around the deal.

The Operational QoE as the standard for dental M&A

It can be used once, for a single transaction, or across the whole lifecycle of the business. For most operators, it should not be a one-time thing.

A buyer acquiring once, or an owner selling once, get the full value from a single engagement. But the same recoverable revenue and the same risk to whether the earnings will hold sit underneath every major decision a group makes, which is why the operators who treat this as a standing part of how they run tend to compound the advantage.

On the practices a group already owns and intends to keep, with no deal anywhere in sight, a Portfolio Operational QoE Review finds the leakage dragging current earnings and hands over the roadmap to recover it, purely to make the business they already own worth more and run better. This is for operating use, an internal tool, not a deal document. And when the group acquires, an Acquisition Diligence Operational QoE on each target means it makes their decisions on real, achievable earnings and sidesteps the deals that look better than they are. When the group prepares to sell, a Pre-Listing Operational QoE captures the upside into the trailing earnings buyers will price on. And as it lists, a Going to Market Operational QoE documents the operational picture so it controls the story and the buyer's diligence cannot chip the valuation.

The reason this matters even for groups that are already winning is simple: nobody measures this layer as a standardized number, so even strong operators are leaving real money in it without knowing the size of it. Good practices still have lapsed patients and unbooked treatment. Growing groups still buy practices here and there whose growth was never sustainable. The difference between a group that does great and one that consistently, decisively outperforms is rarely the big strategic moves; it is whether they capture the value everyone else leaves on the table, deal after deal, year after year. That is why we recommend it as the standard.

Example of a 12-location DSO using the Operational QoE

Picture a 12-location group with around $24 million in collections that is planning to grow for a few years and then sell. The numbers below are illustrative and deliberately conservative, but the shape is how this plays out.

It starts with a Portfolio Operational QoE Review on the 12 locations it already owns, when there's no deals in sight. The review surfaces roughly $700,000 a year of recoverable production sitting across the group: lapsed patients no one is reactivating, treatment already accepted and never booked, two locations whose providers are producing well below the rest. The group works the roadmap over the next year and captures most of it, lifting earnings by around $500,000. At the roughly 8 times earnings a platform this size trades on, that is $4 million of enterprise value created before it buys a single thing.

Over that same year it acquires five practices, one at a time, and runs an Acquisition Diligence Operational QoE on each. Across the five, the analysis finds about $400,000 of recoverable revenue the group can start capturing the day each deal closes. It also catches two things the financials hid. On one target, revenue looks steady but the active patient base has been shrinking for two years behind a string of fee increases, so the earnings are set to fade rather than hold, and the group reprices and restructures around that instead of paying for growth that is not coming. On another, the new patients driving the growth story are barely being retained, so that growth is a treadmill, and the group negotiates roughly $300,000 off the price. Five deals, each priced on what is actually there instead of what the seller's numbers implied.

A couple of years later, now 17 locations and ready to exit, the group runs a Pre-Listing Operational QoE. It surfaces another $600,000 of recoverable production built up across the larger group, and the group captures it into earnings before going to market, lifting the trailing number by about $500,000. At 8 times, that is another $4 million on the sale price, built entirely from patients it already had. Then, as it lists, a Going to Market Operational QoE documents the operational picture so the buyer's diligence has nothing to discover and weaponize, and the earn-out is built on assets already on the books rather than promises about the future.

What happens without the Operational QoE

Now imagine if the same 12-location DSO had never used the Operational QoE.

The $700,000 of portfolio leakage stays invisible, dragging earnings every single year and costing roughly $4 million of enterprise value it never builds. It overpays on the practice whose base was fading, watches those earnings underperform the model, and absorbs the loss after the wire clears. It pays full freight for the treadmill practice, the $300,000 it could have negotiated off gone. It lists on lower earnings and leaves the pre-listing upside, another $4 million of sale price, on the table. And at the closing table, the buyer finds the undocumented gaps and grinds the price down anyway, comfortably another $500,000. Same group, practices, and market. The only variable is whether anyone measured the recoverable revenue and the earnings risk before each decision. Across the cycle, that variable is worth the better part of $10 million, before you even count what the captured earnings would have compounded into over the hold. That is the difference between a group that meaningfully outperforms and one that never quite understands why its returns lagged the high expectations.

How an engagement runs

The engagement is built to run alongside a deal that is already moving, as an extension of your side of it rather than another firm parachuting in. The process is the same whether you are buying or selling.

• A scoping call. Fit, location count, deal stage, timing, and how you intend to use the report. One day.
• Paperwork. A mutual NDA and an engagement letter. One to three days.
• Intake and the data request, sent together. We work through one coordinator on your side, usually the VP of operations, the COO, or a regional manager. The coordinator completes a short group overview form, and each office manager completes a short per-location form and exports a fixed set of standard reports from the practice management system, each covering the trailing 24 months, uploaded through a secure Dropbox file request we provide: recall and continuing care statistics; treatment plan approval, presented, accepted and completed, by provider; the schedule summary, scheduled, completed, canceled and failed, by month; provider production and collections; patient activity, the active count and patients with no visit in 12 months or more; new patients by month; and the adjustment summary, so the conversion to cash runs on the practice's own write-off rate. Counts and totals only, no names, no ID numbers, no dates of birth, so a mutual NDA covers it and no business associate agreement is needed. When we work with a buyer on acquisition diligence, the seller's side facilitates the export and the files come to us from that side, which keeps the analysis independent of the buyer. Three to five days.
• Analysis. We standardize the exports, measure the opportunity in each of the five categories, trace each one to its probable driver, and convert it into dollars on your own cost stack. If anything material cannot be settled from the data alone, one batched set of written questions goes to the coordinator. Two to three weeks.
• Delivery. Within four weeks of complete data, into your data room or by secure link, to the party who commissioned it and nobody else. A buyer's findings stay with the buyer, a seller's never reach the buyer. Questions are answered in writing, and a walkthrough of the findings is available on request.
• Follow-up. At 6, 12, and 24 months we compare the report's figures against what was recovered, at no cost, so you see whether the number held.

Start to finish it runs in weeks, alongside the work already happening, and we never need your model or your own analysis.

Why DRAI

We do one thing, in one industry: we turn dental practice data into what a practice is actually worth in a deal. Not healthcare broadly, not operations in general. Dental practices, every single day. That focus is the whole product. It is what lets us benchmark a target against the dental practices we have already measured, trace each gap to a root cause we have seen before, and put a defensible number on it, the kind of depth you only get from looking at the same thing, deal after deal, and nothing else.

Every engagement makes the next one sharper. We are building a record of what we measured before a deal and what actually happened after it, practice by practice, deal by deal. Over time that becomes a proprietary picture of cause and effect in dental operations: what a given gap is really worth, which problems are fixable and which are not, and how an estimate made before close compares to the recovery after it. Nobody can buy that dataset. It only comes from doing the work at volume, and it makes every number we put out more defensible than the last.

We put our name on the numbers and stand behind it. In a world where anyone can generate a confident-looking analysis with AI in an afternoon, a firm that stakes its reputation on the number being right is a fundamentally different thing from a document that just looks the part.

Also, we were first. Nobody else was putting an independent dollar figure on the operational side of a dental deal, the recoverable revenue and the durability of the earnings, to a standard a data room would accept. We defined that and named it the Operational QoE. When it becomes a normal part of how dental deals get done, and it will, it gets done in the shape we built, the way quality of earnings itself went from a novel idea to something no serious deal closes without.

Who this is for

This is built for the owner or group that is business-minded and treats a practice as an asset, not just a job and passion-project, and would rather find the gaps and fix them rather than hand a buyer all the room for growth.

On the other hand, it's built for the serious acquirer, a DSO, a private equity platform, a strategic buyer, who wants to know exactly what they are buying, exactly what they can pull out of it, and exactly where the risk sits, before they commit.

It works on a single practice, emerging and mid-sized groups, and on platform-scale transactions. And it works for the people around the deal, the brokers, advisors, and attorneys who want their client's transaction to close clean and at the right number.

Is it a zero-sum game? Not entirely, but as you can tell there's definitely asymmetric leverage to whoever holds the alpha in a given transaction.

We take a limited number of engagements at once, because each one sits inside a live deal with a real clock and we protect our turnaround. If your deal is time-sensitive and we are already at capacity, we will tell you straight and give you a date for when we could be available.

About DRAI, and why now

I'm Andres, the founder of DRAI.

I was born in Venezuela and moved to Australia when I was five with my parents. Now I live between the US and Australia.

For most of my childhood I wanted to be a doctor, I grew up genuinely obsessed with medicine and healthcare was never abstract to me. I actually spent more of my own time in hospitals and having operations than most kids do, and dentistry in particular left a mark on me because an orthodontist who fixed my breathing and my bite as a teenager is a big part of why I care about this field at all.

I did not end up in medicine, entrepreneurship pulled me in harder, but the pull toward healthcare never left, and it's no accident that the thing I've bet my twenties on sits right where this industry and real value meet.

Before DRAI, my work sat in valuation and early-stage investing. I did marketing and business development for venture-backed companies, and I spent years taking my own positions on what young companies were worth and then living with those calls. Pricing an asset on what is in front of you, rather than what it claims to be, and being accountable for that judgment, is the exact discipline this firm runs on. It also taught me, mostly the expensive way, the lesson that became DRAI's whole premise: making money and keeping it are two different skills. The durable returns never came from chasing the next exciting thing. They came from the unglamorous fundamentals, retention over acquisition, systems built to monitor what matters, staying proactive instead of reactive, and an honest read on the numbers, the bridge between how a business truly runs and what it is worth. Every business I touched told the same story: everyone obsesses over winning the next customer while quietly bleeding the customers, and the revenue, they already have. That is the thesis behind DRAI.

The way I am wired is to look at how an industry actually works, find the place where everyone has quietly agreed not to look, and go straight at it. In dental M&A that place was obvious once I saw it: hundreds of millions of dollars change hands every year on financials checked to the decimal, while the operational reality underneath, the thing that actually determines whether those earnings hold, almost never gets verified independently, and never to the depth a financial QoE brings to the books. I didn't invent that gap, I just refused to accept this is how it has always been done as a good enough reason for it to stay that way. Then I spent months pressure-testing the idea against the most experienced people in the industry: brokers, M&A attorneys, healthcare bankers, DSO founders, partners at financial QoE firms, venture partners, board directors and more. Every one of them told me the same thing from inside their own corner of it: this is real, it is big, and nobody is doing it.

So here is the future I foresee, and the bet I am making: one day, no dental practice will change hands without an independent read on what it can really earn and whether those earnings will last, measured in dollars, the same way no serious deal closes without a financial QoE today, and DRAI is going to be the firm that made that the standard. It will not happen overnight, because changing how an industry runs its diligence is slow, and proof has to arrive before belief does. But the shift that makes it inevitable is already here, and the edge is always biggest before everyone has it. The brokers, advisors, and buyers who build this into how they work now are the ones who win the next decade of dental M&A.

To summarize

• A financial QoE confirms the earnings were real. The Operational QoE answers the two questions it cannot: how much more the practice can earn from the patients it already has, and whether those earnings will hold.
• We measure five categories of recoverable production, lapsed recall, unscheduled treatment, no-shows and cancellations, provider variance, and new patient retention, in dollars, from the practice's own data, and hand over the roadmap to capture it.
• None of it is secret. It goes uncaptured because nobody measures it independently, at depth, before the deal, and the tools practices already run were built to operate a practice, not to value one. This is the gap DRAI solves.
• For buyers: price each deal on real, measured potential instead of a guess, build your value-creation plan around exactly where the upside sits, and capture it from day one so it compounds across the hold and lifts your IRR.
• For sellers: capture the upside into your trailing earnings before you list, and walk into diligence with the gaps already documented so they get priced fairly instead of used against you.
• Independent by design. We run the analysis but we do not run the recovery. We have no incentive to inflate the numbers, so both sides of the table can trust it.
• One standard across the whole lifecycle: a Portfolio Review on what you own, Acquisition Diligence on what you buy, and Pre-Listing then Going to Market on what you sell.
• A new category, defined and named by DRAI. The edge is always biggest before everyone has it.

Why year-one underperformance gets blamed on integration, the explanations are almost always the same. Whether it's because "integration took longer than expected", or "the staff needed more time to adjust", or "the systems created friction the team hadn't anticipated"...

Integration noise becomes the catch-all for everything that disappoints, and since it's present and visible, it absorbs the blame naturally. The problem with this is that most of what gets attributed to integration was already there before the wire even got transferred. The lapsed recall volume, the unscheduled treatment sitting in the PMS, the no-show patterns concentrated around specific providers, none of that just randomly appeared after close. It was already in the practice before the buyer ever walked in, and it was never documented, which means nobody can prove it.

That's the attribution problem nobody talks about in dental M&A. Without a pre-close operational baseline, there's no reference point to distinguish what the buyer inherited from what the buyer caused. So when month six looks worse than the anticipated model, integration friction gets the blame, the ops team takes the heat, and the deal team moves on to the next acquisition having learned nothing accurate about what they underwrote. Then the exact same assumptions go into the next deal, and the same gaps get inherited again.

A pre-close patient-level operational document changes that. Not because it fixes anything, that's the ops team's job after close, but because it creates the baseline that makes honest attribution possible for the first time. It tells you for example what the lapsed patients was before you arrived, why it accumulated, what it represents in recoverable revenue at the deal multiple, and what it takes to address it in the first 90 days. The ops team walks in knowing exactly where to focus instead of spending the first quarter mapping the practice. The deal team knows what they actually underwrote instead of what they assumed. The fund's return model gets protected, because the operational upside that was priced into the buy-thesis starts getting captured in month one instead of month thirteen. And the acquisition that would have underperformed behind a convenient story about integration friction instead now has a reference point that tells everyone in the room exactly what was inherited, what it's worth, and what capturing it actually requires.

Most acquisition teams modeling upside on a dental practice are working from the same assumption, which is that their integration playbook will deliver roughly what it has on previous deals, and that the gap between what the practice currently produces and what it could produce will close on a predictable timeline. For groups that have done this enough times to have real data behind that assumption, it's been defensible. The averages held and the playbook worked, so going deeper into each individual practice before close didn't feel necessary because the outcomes were fine even without it.

But that assumption is becoming harder to defend. Multiple compression, a higher cost of capital, and PE ownership structures that demand faster and more measurable value creation have made the gap between a deal that performs to model and one that doesn't way more consequential than it was just a few years ago. Delayed recovery timelines don't just shift IRR curves, they consume the capital and bandwidth that should be going into the next acquisition, and in a market where deployment pace matters as much as deal quality, a portfolio carrying meaningful underperformers is a harder story to tell to the people who funded it.

The reason those underperformers so often look like surprises is that the information that would have predicted them was never part of the diligence. Six to twelve months post-close, when the numbers come in short and the board is asking why, the answer is almost always the same: the practice wasn't what the model assumed it was, and there was no way to know that without looking at data nobody looked at before close. Not the financial statements, not the seller's summary reports, but the actual patient-level picture inside the practice management system that shows the lapsed patients, the accepted treatments that were never converted, what the providers are producing relative to each other, and the why behind the variance. That picture can exist before the deal closes, it just isn't currently part of the diligence process because nobody has built the product that produces it for a deal room. Which means every group doing acquisitions right now and the banks underwriting them are running the same blind spot into their deals and excusing the underperformers as bad luck or difficult post-close integration when it's actually neither.

The groups that start acquiring with this level of pre-close clarity first will be pricing deals with a level of certainty nobody else in the market has right now, building more defensible investment theses, and capturing upside their peers won't even know they missed.

When a corp dev team prices a dental acquisition, the premium paid above trailing earnings is justified by what the deal team believes the practice can produce once their systems are running. But that number is built from historical financials and seller conversations, with one being backward looking and the other coming from the person most incentivised to be optimistic. Neither tells you what the practice actually contains right now at the patient level, whether the revenue base is structurally sound or quietly softening, or whether the upside being priced is real and recoverable rather than assumed and unverified. The premium being paid is justified by future performance, but the data that actually speaks to future performance is not even in the diligence package.

At a more serious scale of 50 to 100 acquisitions a year with a PE mandate to show precise returns, that gap starts costing real money.

In a practice doing $1.5M in collections, a forensic PMS analysis can surface $150K to $300K in recoverable revenue that never appeared in the financials. Such as lapsed recall worth $80K to $150K, $60K to $120K of accepted treatment never scheduled, and 30 to 40% provider variance causing a $60K to $120K production gap. At a 6x multiple, $200K in recoverable revenue sitting unquantified in the PMS is $1.2M in enterprise value the deal team had no visibility into when they set the price.

Across 80 acquisitions at $200K average recoverable per location, that's $16M in patient-level revenue priced on assumptions, annually. So practices with less recoverable upside than assumed actually underperform their model and compress IRR. While practices with more were acquired without the precision to bid aggressively on what was justified. Both outcomes affect the returns the fund reports, the carry the investment team earns, and the mandate they receive for the next deployment cycle. Portfolio revenue growing in high single digits looks fine at the group level but the IRR on individual deals where the upside assumption was wrong does not.

What changes this is not adding another analyst to the diligence team. The PMS data requires a forensic methodology, deal-room formatting, and benchmark context that doesn't exist inside a standard corp dev process, which is exactly why no current diligence package includes it.

The Operational QoE runs post-LOI concurrent with the financial QoE. There's no timeline delay or friction. It's a deal-room document showing specific recoverable figures per category, dollar amounts, and the operational reasons behind each gap, so that the price the investment committee approves is built on what the practice actually contains, and the integration team starts executing on day 1 with a targeted plan rather than a standardized playbook.

Every acquisition priced without this layer is being approved on an incomplete picture. The groups that start building it into how they underwrite will reduce risk and price with a precision others cannot match.

Every dental buyer enters an acquisition knowing there's upside to capitalize on. That's why the question shouldn't be whether opportunity exists, it should be whether you know pre-close exactly where the gaps are, the specific root cause of them, and the dollar value they represent. Right now in dental M&A, most are figuring that out through twelve months of running the practice after they've already bought.

Without a formal operational picture pre-close, the buyer discovers the baseline organically over time. Hygiene production drops in month three, someone investigates in month five, the recall breakdown gets identified in month seven, a fix gets built in month nine, and execution starts in month eleven. The information surfaces, it always does, but it surfaces incidentally through operations rather than deliberately before the deal closes. So by the time the buyer knows exactly what they're working with, they're already twelve months into a hold period that was supposed to be generating stronger returns.

Consider a fund acquiring a practice for $5M targeting 20% IRR over five years. An Operational QoE run post-LOI surfaces $550K in dormant patient revenue across lapsed recall, unscheduled treatments, and no-show patterns. Weighted for realistic recovery probability, $320K is convertible within six to twelve months. At 70 to 75% incremental margins, that's roughly $230K in incremental EBITDA captured in months one through six rather than months twelve through eighteen. At a 6x exit multiple, that's $1.38M in enterprise value. And with the root causes already identified before Day 1, execution starts immediately rather than after a year of figuring out where and why the gaps exist.

The same picture that takes twelve months to surface organically takes two to three weeks to extract intentionally before close. The difference is sequence. Because one produces a Day 1 execution plan while the other means you spend year one figuring out what you should have known before you closed.

Your current diligence process shows you what the practice earned, but it doesn't tell you what operational value is sitting dormant in the patient base, why it never converted to revenue, and what it's worth at the deal multiple. Without that picture you are pricing and acquiring an asset you only partially understand. That is the gap the Operational QoE closes.

If your acquisitions are consistently missing EBITDA benchmarks in year one and you keep blaming integration friction, the actual problem is likely sitting in the PMS data that nobody properly looked at during diligence.

I spoke with someone who ran operations at a PE-backed DSO with 100+ locations. Every acquisition missed its year-one EBITDA target, and integration was the excuse. But most of what got blamed on integration was already there before the deal closed. It just wasn't documented in the deal room, so when the ops team spent months on discovery instead of execution they got blamed for slow results even though they walked in with zero visibility into what needed fixing.

Whether it's lapsed patients representing hundreds of thousands in recoverable revenue sitting in the PMS, or unscheduled treatments accumulating for months, or provider variance where one doctor produced at half the rate of another doing identical procedures. None showed up in trailing EBITDA. The deal closed based on assumptions and the ops team spent six months figuring out what was broken. So by the time discovery finished and improvements started flowing through financials, nine months had passed. The practice had missed its target, the ops team was taking heat, and the deal team moved on to the next acquisition with the exact same costly blind spots.

The gap is that operational opportunities live in the PMS as patient-level patterns that don't show up on the P&L. Standard financial diligence has no way to find them even though they're completely documentable and executable.

Operations knows what to look for in the PMS but doesn't have bandwidth to do forensic analysis on top of running the existing portfolio. Meanwhile, finance teams know how to build models but don't know which PMS reports reveal operational upside or how to translate patient patterns into recoverable revenue at the deal multiple.

A pre-close operational diagnostic solves this: PMS-level forensics documented in financial terms your deal team can underwrite, with an execution roadmap for ops from Day 1 onwards. Lapsed recall becomes recoverable revenue with patient counts and capture timeline, unscheduled treatment becomes EBITDA capture with ownership assigned, and provider variance becomes margin improvement with root cause and protocol fix.

When that exists alongside financial diligence, your models stop being built on assumptions and start being built on documented baselines. Your ops team walks in knowing what to execute instead of spending a quarter on discovery. So the acquisition that would've missed its target now has quantified proof of what was inherited and what capturing it requires.

That's why the systematic EBITDA misses aren't an execution problem. They're a documentation problem. You're inheriting operational gaps that exist before you close, modeling improvements without validating what actually needs fixing, and discovering the real operational picture six months too late.

Most due diligence on a dental group acquisition is financial. Revenue, EBITDA, payer mix, lease terms, provider contracts, and the numbers generally tell you whether the practice is profitable and whether the deal makes sense on paper. But what almost nobody audits is how much revenue is sitting uncaptured inside the operations you're about to acquire, and that gap is where the real economics of the deal get shaped without anyone at the table realizing it.

That operational layer lives inside the PMS at the patient level, and pulling it out requires a specific kind of analysis that most diligence teams aren't built to do. It's the difference between knowing a practice produces $X in revenue and knowing that $X is actually $200K to $300K lower than what the same patient base should be producing under standardized systems. One of those numbers tells you what the practice is, but the other tells you what it could be, and which one you're basing your offer on changes everything about the economics of the deal.

If there's $300K in annual revenue sitting recoverable inside the operations and you don't know about it going in, you paid a price based on earnings that were $300K lower than what the practice is actually capable of producing. At a 6x multiple you effectively overpaid by $1.8M for upside you didn't know existed. If you do know about it going in, you can either negotiate the price down because the seller never captured it or you close knowing you have a revenue acceleration plan ready for day one that wasn't priced into the deal. Either way, you're in a completely different position than the buyer who only looked at the financials.

The groups and funds that acquire most successfully aren't just running better financial diligence, they're the ones who understand exactly what the operational picture looks like at the patient level before they close and have a specific plan for what to do with it the day the keys change hands. That's the difference between acquiring a practice and hoping the numbers improve versus knowing exactly where the improvement is going to come from and how fast.

In dental M&A the financial QoE gets outsourced without a second thought. You don't run it in-house and you don't simply take the seller's numbers, you commission an independent third party to hand you a data-room document that says what the earnings actually are, and everyone treats it as settled because nobody with a stake produced it. The process is sound, but the hidden missed opportunity is that it stops at the financials.

The operational layer of the same group, the recall that quietly went cold, the treatment accepted and never scheduled, the no-show pattern that swings wildly between locations, is what increasingly decides whether the deal performs, yet it gets none of that treatment. At best, a buyer kicks the tires qualitatively. But nobody commissions an independent, quantified, location-by-location read of it, so the number that says what those gaps are worth never exists. It's not that it doesn't matter, it's that doing it properly is hard in a way the financials are not: patient-level data needs to get pulled from every location's PMS, normalized across sites that run differently, and made defensible enough to survive scrutiny post-LOI. No existing role can take it on, so it gets left for the buyer to discover by living inside the practice for a year. And that's where it gets costly.

You deployed the capital on the half of the picture you could see, and the half you could not is what's driving the return. The recall was colder than represented, the acceptance rate softer, half the locations bleeding chair time nobody had counted, and none of it was visible the day you set the price. So the first time the deal is reviewed against model it is behind, and you're the one who brought it to the committee, explaining a shortfall you cannot cleanly attribute because you never even established what you inherited. The plan slips, the number gets revised down in front of the people who trusted it, and the same blind spots roll into the next practices you tuck in. At the multiple, that unpriced gap is seven figures either overpaid to the seller or left in the practice to chase after close. And the multiple arbitrage that once absorbed the gap at exit is gone, holdbacks have expanded, and returns reliably come from how each practice actually performs. So the operational reality you never established is the one your IRR now depends on.

Luckily, the fix is the one you already use everywhere else. An independent read produced by a firm with no stake in the deal, quantifying the opportunity straight from the PMS: the recoverable revenue and what it's worth at the multiple, traceable line by line. It is the operational counterpart to the financial QoE, and it belongs in the same data room.

Every dental M&A transaction has a financial quality of earnings but the operational layer underneath it has never been built into the diligence stack.

Financial QoE firms know audit and accounting. Dental consulting firms know operations and they help owners run better practices over months and years, but they don't produce forensic documentation of the gap between earned and capturable revenue for a transaction event. Brokers facilitate transactions, but forensic operational reviews on every listing is not in scope. Internal operators run the business yet rarely produce buyer-grade documentation about their own performance gaps, for obvious reasons.

No category of advisor is set up to produce the Operational QoE. It's a structural absence. So the work of documenting that operational layer does not get done. Buyers underwrite without it, close the acquisition, and discover the true operational picture themselves months later when their integration team opens the PMS. Lapsed recall, unscheduled treatment, provider production variance, no-show patterns, retention curves that bleed value over 18 months. All of it has been sitting in the software the entire time, but by the time the buyer's team finds it the purchase price is fixed and the discovery becomes a value creation problem instead of a transaction input. The seller left it on the table, and the buyer absorbs it as integration work. Everyone moves on and the cycle repeats on the next deal.

This was tolerable when dental PE was running on multiple arbitrage. Buy at 5x, roll into a platform, exit at 12x, and the operational layer inside each tuck-in worked itself out at the platform level. The arbitrage was the return and the diligence stack was built around that thesis.

But we all know that thesis is breaking. More than 40 DSOs were brought to market in the past two years and less than 10 closed. Hold periods stretched from 3 to 5 years out to 5 to 7 plus because operational reality at each tuck-in did not match what was sold and the problems compounded platform-level. Sellers used to get 100% cash at close, now they get 65 to 70% with the rest in holdback tied to operational performance. Entry multiples crept up, lender leverage came down, and LP pressure on PE returns is rising. The exit math no longer survives operational surprise.

That's why the next wave of buyers cannot rely on the old underwriting model. The return cannot come from rolling the asset into a bigger platform exit, because that exit math no longer works. It has to come from running the specific practice better than the seller did, which means the buyer needs to know what the practice is actually doing today, before they sign the LOI.

Financial QoE cannot answer that question, and neither can anything else in the current diligence stack. Our Operational QoE is the piece of diligence that does. It quantifies the opportunity: what the practice should be earning, with patient-level evidence the buyer's own ops team can validate.

Most dental groups going to market have hundreds of accepted treatment plans sitting unscheduled across their locations, and the EBITDA the deal gets priced on reflects none of it.

The seller goes to market with a clean financial QoE, the deal gets priced, diligence runs its course, and the transaction closes. Every professional at the table executed their scope well, but sitting inside the PMS across those locations the entire time was a patient cohort that already said yes to treatment, already had it diagnosed and presented, and never got a follow-up call to schedule it. Across a six to ten location group that backlog typically runs 400 to 700 cases annually, and at average case values it represents $180K to $350K in revenue the group should have captured yet didn't.

The problem is that nobody evaluated it. The CPA's scope is financial normalization, not pulling unscheduled treatment reports from every location and mapping why the conversion rate at Location 5 is half what it is at Location 2. The broker's role is positioning the group and managing the deal, not diagnosing why the treatment coordinator process broke down at three offices after turnover. The buyer's diligence is mainly just built around the financial and legal picture. And the lender just underwrites against the EBITDA they receive without evaluating how consistently it gets produced across sites.

Every professional is doing their job correctly, but the operational layer sits between all of them without an owner, quietly suppressing the number the entire deal gets built around.

The cost of this is specific. That unscheduled treatment backlog flows straight into the EBITDA gap, and at 5x to 6x multiples on a mid-market group it's $900K to $2M that transfers from seller to buyer because no document ever surfaced it. The broker's commission gets calculated against a deal that was smaller than the group warranted, and the lender underwrites against earnings that don't reflect what the group is actually capable of producing.

None of them even find out because the analysis that would have surfaced it doesn't get produced at any stage of the deal by anyone.

A dental practice going to market can show clean 12% YoY growth on the financials while still also having 30 to 40% of its diagnosed treatment sitting unscheduled in the PMS. This is where deals get priced sub-optimally, as the buyer is paying a multiple of EBITDA that assumes the current growth rate continues while that growth rate comes from a practice that isn't even converting 30 to 40% of what it already diagnoses.

Thing is, the buyer isn't just paying for the EBITDA, they're paying for a trajectory, and the trajectory they're underwriting is built on top of a broken conversion pattern nobody is quantifying. If the target was growing 12% while leaking a notable amount too, a few things become immediately relevant to the buyer that rarely get quantified pre-close.

First, the growth rate is structurally capped. You can't compound 12% forever on top of a practice that's converting a fraction of what it diagnoses, because the unconverted pile gets bigger every quarter and eventually the capacity to convert it caps out before production does. The buyer underwrote a growth curve that the operational reality of the practice can't actually sustain, and nobody ran the numbers on where the ceiling is.

Second, the conversion pattern itself tells you what you actually bought. A practice leaking 30 to 40% of diagnosed treatment has a specific operational profile, whether it's treatment-plan presentation failing at the front end, no systematic follow-up on accepted plans, a scheduling coordinator who left six months ago and was never replaced, or a provider who doesn't close treatment. The buyer walks in without really knowing which of those they're inheriting, how expensive it is to fix, or whether the seller staying on 12 months post-close helps or hurts.

Third, it directly changes what the real run-rate EBITDA looks like. If you work through the backlog over 18 months, EBITDA steps up meaningfully in years 2 and 3 in a way the model didn't capture. If you can't, year 1 EBITDA comes in below the underwriting number because the growth rate that was baked into projections was riding on conversion weakness that doesn't fix itself under new ownership.

Dental PE has moved from multiple arbitrage to operational execution, and the old diligence stack was built for the world where year 1 operational reality was assumed to work itself out. But over 40 DSOs were brought to market in the past two years and less than 10 closed, all because the operational reality at each tuck-in did not match what was sold and the problems compounded platform-level.

None of this gets properly quantified pre-close because the backlog rarely makes it onto the table. The financial QoE answers what was earned, but the Operational QoE answers what is actually capable of being earned and what happens when a buyer inherits the gap.

If you've started thinking seriously about what your group is worth and what an exit actually looks like, the thing that almost never gets talked about is that most owners go to market with earnings that are lower than they should be and never realize it. Not because the practice isn't profitable, but because there's revenue sitting uncaptured across the locations that's been quietly suppressing the number your entire valuation is based on.

Dental groups typically sell at somewhere between 5x and 8x EBITDA depending on size and structure and buyer type. So if you're leaving $300K uncaptured annually, you're not just losing $300K a year in revenue, you're getting valued on earnings that are $300K lower than they should be and that gap gets multiplied across the entire deal. At a 6x multiple, that's $1.8M less on your sale price. At 8x, it's $2.4M. That's not a rounding error, that's a life-changing difference in what you walk away with, and it came from revenue that was always yours to capture.

The owners who end up in the strongest position going into a sale are the ones who found those gaps 12 to 18 months early, recovered the revenue, and walked into the process with earnings that actually reflect what the practice is capable of producing. That does two things at once: the number your valuation is based on goes up because you've been capturing revenue you weren't capturing before, and the operations behind that number are documented and standardized and clearly sustainable which gives the buyer confidence that the improvement isn't temporary. Both of those move the multiple in the seller's favor and together they compound into a difference that can be seven figures depending on the size of the group.

Most owners who've spent 15 to 20+ years building a group have naturally focused on clinical work and patient relationships and adding locations and managing staff. But the operational fine-tuning that makes a practice truly sellable at a premium doesn't naturally happen in that environment because the incentives are completely different when you're building versus when you're preparing to exit. It's a fundamentally different project and the shift from growing the practice to making it optimally valuable to a buyer is one that benefits from someone looking at the operations with a very specific lens.

What you genuinely don't want is to sell and then watch the buyer capture $300K in revenue from your own patient base in their first year using systems you could have literally built yourself 18 months earlier. That revenue was always yours to recover, and every dollar of it would have flowed into the earnings your deal was priced on.

Every group I talk to that are planning their next acquisition tend to focus on the next location, the next deal. But from my perspective they're not looking hard enough at what's really going on in the ones they already own. It makes sense though, because expansion feels like progress. Buying the next practice is visible, tangible momentum that shows the group is growing. But growth on a fragile foundation isn't really growth. So although optimising what you already have is less exciting, it's what determines whether the expansions are even sustainable.

If a group has say 8 locations, with full schedules, collections looking fine and everyone busy, but underneath that there's lapsed recall nobody's worked in months, countless treatments that got diagnosed and never scheduled, one provider producing 35% more than another for reasons nobody's investigated, or no-show rates twice as high in two locations than the rest. What does that tell you about how the next locations are going to go? This sort of important data and context doesn't show up in the P&L, yet it all represents real value. If you're not taking it into account, you're buying location 9 which will end up with its own version of the same leaks. And before you know it, you're running the same suboptimal performance across even more locations now.

This all matters because of how it impacts your capital. The cash you'd use to fund good expansion is partly sitting inside your existing practices right now, uncaptured. Recover it first, and your next deal is funded by performance instead of purely by debt, and in 2026 this difference matters. The cheap debt that made roll-ups easy is gone, hold periods have stretched, and I believe buyers and sponsors will increasingly be less willing to pay for growth potential, and more focused on how each location performs. Same-store execution is the number that matters now of course, and adding locations on top of weak ones doesn't hide that anymore but actually compounds it.

This is why the sequence I'd argue for is contrary to the norm. Before you expand, get a real read on what the practices you already own are capable of producing versus what they produce today. A proper quantified picture of where the recoverable revenue is, netted down to what's realistically recoverable, location by location, provider by provider. Fund from that first. Then expand from a base that works, into deals you can underwrite with your eyes open because you finally know what good looks like in your own group.

The groups that scale well aren't the ones that buy fastest, or even the ones that buy the best deals. They're the ones whose existing locations are already running at what they're capable of before they add the next one.

A few days ago I posted how dental groups should improve their existing locations before they expand. My friend David Eslinger, who has spent 35+ years in the industry, dropped a great comment that I wanted to address here.

His point was essentially that groups are sitting on years of unaddressed operational issues because of how the early consolidations were sold in the first place. Owners were told nothing would change, to keep running things their way. Which was good for closing deals but bad for operations. The selling dentist got paid, coasted toward the exit, and had little reason to fix problems they'd tolerated for years. So the portfolio fills up with baked-in neglect that nobody inside has the will or the authority to touch.

David then asked me something important. Can the sponsor actually require the fixes? And with more states tightening the rules around corporate influence over dental practices, at what point does a sponsor pushing operational change start to look like the kind of interference those laws are meant to stop?

He's touching on a real bind, and I don't think you resolve it by having the capital partner lean harder on the practice. The more a sponsor reaches directly into how a practice is run, the more it looks like exactly what the new laws are circling.

The thing is, the difficult part was never seeing that a practice is underperforming. Everyone can feel that. The hard part is that the people who can legally act on it, the dentist and the clinical leadership inside the practice, often don't have a clear, quantified reason to, and the capital side that wants it fixed can't be the one directing the fix.

This is why DRAI addresses that gap. Our Operational QoE doesn't tell anyone what to do, it puts a defensible number on what revenue is actually recoverable, where, and why, and hands that independent analysis to whoever is allowed to act on their part of it. The dentist decides what happens clinically. Operations handles what's operational. The capital side gets an honest number to decide from, and the people who are allowed to fix things finally have the clarity to do it. No one has to overstep for any of it to happen.

That's the part I find genuinely interesting about where this is heading. As the rules tighten on who can direct what, a neutral, independent read becomes even more useful. It's one of the few things that surfaces the problem without anyone overstepping.

If you're operating a PE-backed dental group, the board conversation about EBITDA improvement comes around every quarter and the pressure to show margin growth doesn't just pause while you figure out where to find it. The obvious levers get pulled first, like renegotiating supplier contracts, tightening labor costs, pushing case acceptance, or investing in marketing to drive new patient volume, but most of those either take time to show results or have diminishing returns because they've already been optimized once or twice since the acquisition.

The lever that almost never gets pulled is the revenue that's already inside the operation but not being captured. The beauty is that this revenue drops almost entirely to the bottom line because the overhead is already absorbed, the chairs already exist, and the staff is already on payroll. The patients already said yes to treatment at some point, so there's no customer acquisition cost attached to any of it, which means every dollar recovered flows through to EBITDA in a way that new patient marketing never will.

The math on this is what makes it hard to ignore once you've seen it. A group running 8 to 10 locations with the typical operational gaps is usually sitting on $200K to $500K in annual recoverable revenue that nobody is systematically tracking. Even just capturing a portion of that in two quarters changes the trajectory of the EBITDA story in a way that's concrete and defensible because it's built on actual patient data, not projections or assumptions about what marketing might produce.

The CFO or COO who walks into the next board meeting with a specific number quantified by location and category and a recovery plan that's already 60 days into execution is having a fundamentally different conversation than the one who's presenting another growth initiative and asking for patience. One of those is showing the board that there was money already inside the operation that nobody was capturing and that it's now being captured systematically. The other is asking for more budget, more time, and hoping the numbers move.

A dental group showing $1.4M in EBITDA across eight locations can look exactly the same on a financial QoE whether that number is being produced consistently across every office, or whether two locations are carrying the rest while three others have a combined $300K to $400K in revenue they should be generating but aren't.

The financial report doesn't distinguish between those two scenarios because it's not designed to, and nobody else in the transaction evaluates it either. The operational layer, the part that shows how the EBITDA actually gets produced day to day at each site, it just falls between disciplines entirely. No-show rates running double the group average at specific offices because the front desk process is different at every location and nobody standardized it, patients who fell out of recall and were never re-engaged, treatment that was accepted but never scheduled. That kind of variance means the EBITDA being underwritten is concentrated in a few locations rather than distributed across the group, and the moment anything shifts at those strong offices, whether because a lead provider leaves or a competitor opens nearby or volume moves seasonally, the aggregate number starts softening because the underperforming locations have no upward trajectory to offset it and haven't for over a year.

That's a meaningfully different risk profile than an EBITDA where all eight locations are contributing proportionally because the operations underneath are actually systemized, even though both scenarios look identical on the financial QoE the loan gets structured around. Not to mention the earnings have less cushion than the numbers suggest, which means debt service coverage can tighten faster than anyone modeled for.

When the operational picture gets evaluated before the transaction, the lender gets visibility into whether the earnings have real durability across locations or whether they're being held together by a minority of offices that happen to be performing well. That's a meaningful input into how the loan gets structured and how the risk gets modeled, and right now it's a piece of the picture that doesn't get produced at any stage of the deal by anyone.

Bain & Company's 2026 Global Private Equity Report put a number on something dental buyers can already feel yet haven't been able to solve.

They call it 12 is the new 5, because in 2015 you needed 5% annual EBITDA growth to hit a 2.5x return over five years. But today, with borrowing costs at 8 to 9% and compressed leverage, you need 10 to 12%. That changes everything about how you underwrite a dental acquisition.

Let's say a dental practice produces $800K in EBITDA and will close at a 6x multiple for $4.8M. If they do an Operational QoE post-LOI, they may find $300K in dormant revenue from lapsed patients, diagnosed and accepted treatment not yet completed, no-show patterns and cross-location variance. Yet it doesn't appear in the financials. None of it triggered a billing event, never showed up in the financial QoE, and never got factored into your underwriting.

Recovering this dormant revenue doesn't require new staff, equipment, or locations. The fixed cost base is already in place, so most of that $300K flows to EBITDA at 70 to 80% incremental margins. At a 6x multiple, that's $1.25M to $1.44M in enterprise value the buyer is acquiring without even knowing it exists.

If the buyer surfaces this in the first 90 days, EBITDA grows faster than modeled. The exit multiple applies to a higher earnings base, and the fund hits its 2.5x MOIC target in year four instead of year six. That compression means earlier distributions to LPs and faster access to the next fund, even in what Bain calls the most difficult fundraising environment the industry has ever seen.

If it gets discovered in year 2 or 3 though, the model gets revised downward and the hold period drifts. With hold periods already approaching seven years and LP distributions below historical norms, that drift is not a rounding error but a huge fund economics problem.

Bain calls the solution full potential diligence. Their words are that if you understand best what the asset can be worth, you're not only smarter about what to bid for it but you enhance speed to value by hitting the ground running on Day 1 of ownership.

The operational layer inside the PMS is one of the most consistently under-documented revenue levers in dental M&A. It doesn't matter whether you're acquiring a single practice or a twenty-location group, the gap exists in both.

In a world where 12 is the new 5, discovering your operational baseline on Day 1 versus Year 2 is the difference between a deal that performs and a fund that struggles to raise its next vehicle.

PE firms are holding DSO assets for an average of 6+ years. And although the value creation plans look good at close, within 12 months the production per location is actually softer than modeled, hygiene schedules have open chairs, and associates are leaving without anyone having flagged the concentration risk. Thing is, every single one of those problems has a specific quantifiable answer that already exists in the practice management system before the deal closes, it's just that the standard diligence process isn't currently built to look at it.

The financial quality of earnings isn't even the problem, it does exactly what it's designed to do. It validates the revenue, it normalizes the EBITDA, and it confirms the tax picture. But it doesn't ask how many patients have lapsed out of recall, or how much diagnosed treatment is sitting accepted but never scheduled, or which providers are carrying disproportionate production and what happens to the revenue line when one of them leaves. Those are operational questions, and right now they live in the PMS where nobody really touches them during a transaction.

As a result, the acquirer builds a value creation plan with a limited picture based on assumptions about what the practice is capable of producing, and 12 months later the operating partner is finding out those assumptions were wrong. And it's not because the financial picture was inaccurate but actually because the operational picture underneath it was never part of the underwriting. So in reality the hold period doesn't extend beyond 6 years because the thesis was wrong but rather because it was built on a financial model that never included the operational reality underneath it.

What does that look like in practice? Production per location softer than modeled is trailing revenue that was underwritten without knowing what was actually driving it. Hygiene schedules have open chairs is lapsed recall that was already deteriorating before close, measurable down to the patient count. Meanwhile, associate departures no one flagged as strategic risks is provider concentration risk, quantifiable by provider, where one departure can take 30 to 40% of production with it.

There's signs that antitrust enforcement has arrived in outpatient consolidation and not just hospital mergers.

For a decade the regulatory lens has mainly sat on hospitals. Surgery centers, the classic outpatient roll-up, were assumed to be too fragmented and too small to draw antitrust attention. But that assumption is dying, and in a vertical that structurally looks exactly like dental. Hundreds of small sites rolled up fast, by financial buyers, into platforms that are getting large enough to be visible.

Dental is the most consolidated yet least scrutinized outpatient vertical there is. There's more than a 100 PE-backed DSO platforms, thousands of practices absorbed, and some states already moving on corporate ownership of dental practices. We're reaching a point where it matters whether the platforms being built right now are built to survive it.

When that scrutiny arrives, it doesn't just test the legal structure. Regulators, lenders, and the next buyer all end up asking the same underlying question in different words: is the platform actually as good as its financials say?

And the place that question gets safely answered is not the cap table or the MSO agreement, but inside each practice, per location, in the operational numbers nobody really properly documented while the multiple was doing all the work.

That is where the gap lives in my opinion. Financial QoE tells a buyer what each practice collected, not what each practice was capable of collecting and didn't, or whether the trailing EBITDA being underwritten is durable or quietly propped up by a recall system that was already breaking. When a platform reaches recap and a sophisticated buyer finally opens the practice management system, the deals that stall are the ones where the operational reality never matched the financial story. Diligence purgatory is just the polite name for a platform that was never built to be examined at the location level.

The next recapitalisation will not reward whoever acquired the most, but the platforms that can be opened up and examined without the story falling apart.

The most valuable number in a dental transaction is usually the one nobody in the room has measured.

A financial quality of earnings, the analysis every deal runs, tells you precisely what a practice earned. It is rigorous, standard, necessary, but it answers only one question and was never built to answer the second: what the practice should have earned and did not. At deal multiples, that gap is often worth more than the add-backs everyone spends weeks arguing over.

The gap is not abstract. It concentrates in five places we can quantify directly from the practice management system, and every one is revenue the practice already created and never captured. Lapsed recall: patients who finished treatment, were due back, and quietly fell off the schedule. Unscheduled treatment: cases diagnosed, accepted, and never booked. No-shows and cancellations: chair time lost and never rebooked. Provider variance: two clinicians on the same patient flow producing very different numbers. New patient retention: expensively acquired patients seen once and never brought back.

A financial QoE sees none of it, because a collections statement counts the patients who showed up and the cases that closed. It has no line for the ones that did not.

That is the layer we named the Operational QoE. Not an upgrade to the financial QoE, and not a dashboard that recites metrics anyone can already pull. It is the forensic analysis no one runs: it goes into the practice management data, isolates the recoverable revenue buried across those five categories, quantifies what each is worth at the deal's multiple, and names the operational reason it went uncaptured. The raw signals sit in the system. The number that says what they are worth, and the document that makes it hold up in diligence, do not exist until we build them.

It matters now because the way money is made in dental has changed. The decade of buying low and exiting high on multiple arbitrage is over. The return now comes from running each practice better than the seller did. So the buyer who knows where the recoverable upside is before close, and the seller who can prove it before listing, are the ones who control the deal.

Every dental data room already runs the document that measures what the practice collected. The one that measures what it was there to collect has been missing.

Four short pieces published on the DRAI company page, on how the Operational QoE works and what separates it from the document every deal already runs.

Two documents, two questions

A typical Financial Quality of Earnings and DRAI's Operational Quality of Earnings answer two different questions. The deals that go wrong are the ones where someone assumed the former addresses the latter.

The financial QoE is the established standard. It normalizes the EBITDA, reconciles collections to deposits, tests the add-backs, and tells the buyer what the practice actually earned. Every deal should be underwritten on it.

But what it does not do, because it was never built to, is look underneath the earnings at the operations that produced them. It counts the patients who came back, not the ones who lapsed and were never called. It counts the cases that closed, not the treatment that was diagnosed, accepted, and never booked. It records what each provider produced, not why two providers on the same schedule produced very different numbers. It measures what was captured. It has no line for what was recoverable and left behind.

That second layer is the Operational QoE. It sits beside the financial QoE in the same data room, on the same period, built from the practice management data the financial team was never scoped to examine. One document tells you what the practice earned. The other tells you what it was capable of earning, by category, with the reason behind each number.

Use both and you are underwriting the whole practice. Read only the first and you are pricing half of it, and finding the other half in year one.

One report, both sides of the deal

The Operational QoE works on both sides of a dental deal. What changes is the job it does for whoever is reading it.

For a buyer, it runs after the LOI and before close. It shows the recoverable upside and the operational risk inside the target before the capital is committed, handing the new owner a plan to start capturing that value from day one. The result is a stronger IRR and value created earlier in the hold.

For a seller, it runs pre-listing before going to market. It surfaces the recoverable revenue still sitting in the practice, the revenue that can be captured into EBITDA before the business is priced, and documents it so the upside survives a buyer's diligence instead of being quietly discounted. The result is a higher EBITDA going to market and a stronger valuation to defend.

One report. The buyer uses it to buy better and own better. The seller uses it to list higher and hold the price.

What unscheduled treatment looks like in the data

A dental practice can show clean, growing collections every year and still be sitting on a six-figure hole the financial diligence never sees. Take one of the five categories we quantify: unscheduled treatment.

A patient comes in, the dentist diagnoses work that is needed, presents it, and the patient agrees. Then it never gets booked. The crown, the perio, the implant sits in the treatment ledger as accepted and unscheduled, sometimes for years. The practice already did the hard part, the diagnosis and the patient's yes. It just never put the work in a chair.

None of it touches the financials. A financial QoE measures production and collections, which by definition is the treatment that got done. Treatment that was accepted and never scheduled produced no charge, so it shows up in nothing a buyer reads, even though it is demand the practice already created and is owed.

On a six-location group it is common to find thirty to forty percent of diagnosed treatment unscheduled in the system. Convert even part of it and most of that drops to margin, because the patients are already in the database and the diagnosis already exists. At a normal multiple, the enterprise value tied to closing that gap is often the difference between the number the seller expected and the number they got.

The trailing financials show what the practice collected. The treatment ledger shows what it was already owed and never booked. One of those is in the deal. The other should be.

Every number traces back to the practice's own data

Every recoverable-revenue figure is tied to the raw practice management data it came from, laid out in the appendix.

A buyer's analyst can rebuild any figure from the data behind it. A seller's advisor can pressure-test every line before it reaches a buyer. Nothing rests on our word, and nothing needs to.

A number in a deal room is only worth what it can be verified against. Ours are built to be verified line by line. We would rather hand you the data and the math than ask you to take either on faith.

Most dental M&A deals close with proven upside sitting undocumented in the practice management system. The seller has no leverage to negotiate for it, and the buyer discovers it six months later during integration.

Lapsed recall patients, unscheduled treatment plans that never got followed up on, no-show patterns across providers, all of it sits invisible because none of it ever appeared on the P&L and nobody pulled the PMS data to document it.

The reason this happens is structural. Financial quality of earnings audits capture what the practice earned, but they don't capture what should have been earned yet wasn't. That revenue was never collected, so it never touched the P&L. It exists in patient-level data inside the PMS, and unless someone pulls treatment plan acceptance rates by provider, recall reactivation conversion, and scheduling variance across operatories, the gap just sits there until someone decides to look.

Earn-outs get structured around future growth projections, and those projections are always contested because nobody has baseline data to anchor them. The seller can say the practice will grow 15% with the right systems, but the buyer says maybe, maybe not, and we're not paying for hypotheticals. So the compromise becomes an earn-out clause tied to trailing twelve month performance increases, which shifts all the execution risk to the seller even though the buyer controls operations post-close. And many of those earn-outs never pay out.

The distinction that doesn't exist yet in most deals is between paying for future growth and paying for documented assets that already exist. Future growth is a projection. But recoverable revenue sitting in the PMS is documented fact that can be quantified by patient cohort, loss reason, treatment plan value, and time since last contact.

Earn-out clauses are built on speculation about what might happen post-close, but earn-up clauses are built on documentation of what already exists. The legal mechanism is the same, payments over time based on performance metrics. But the justification is fundamentally different, as one asks the seller to bet on the buyer's execution and the other asks the buyer to pay for documented assets they're about to own.

When that documentation exists in the deal room before the LOI, sellers can structure earn-up clauses anchored to capturing specific assets that already exist, rather than betting on earn-out growth targets that may not materialize. Buyers get clarity on what they're buying instead of discovering gaps post-close. And advisors can structure deal terms around metrics both sides can verify.

When that layer gets documented, sellers stop walking away from recoverable enterprise value they couldn't prove existed. Deals stop getting retraded late in diligence because the baseline was documented upfront, and the earn-up versus earn-out distinction becomes meaningful: documented assets against contested projections. One is more valuable than the other.

Every dental transaction has a financial Quality of Earnings. The CPA normalizes the EBITDA, adjusts for add-backs, and both sides use that report to negotiate the deal. That process is standard, expected, and nobody closes without it.

But the financial QoE only covers the financials. It tells you what the numbers are, yet never tells you why they look the way they do.

Nobody in the transaction is diagnosing why one location runs 8% no-shows while another in the same group runs 22%. Or quantifying why treatment plan conversion is 70% at the flagship location but 38% at the office acquired two years ago. Or surfacing how many patients dropped out of their hygiene cycle because the person managing recall best left last year and their process left with them.

That operational layer sits in the PMS across every location. Dashboards have been showing pieces of it for years. But seeing a number on a screen and actually diagnosing the root cause at each site are two completely different things.

Right now, that work simply doesn't get done. Not pre-listing, during diligence, or post-close. Not the CPA, the broker, the buyer's team, or anyone else in the deal.

It falls between disciplines and everyone assumes someone else is handling it. And the cost of that gap is significant.

The seller goes to market with an EBITDA that's understated by $200K to $500K or more in recoverable operational revenue, and at the multiples dental groups trade at, that's $1M to $3M or more missing from the valuation.

The broker's deal closes smaller than it needed to, and the buyer inherits operational leakage that drags post-close returns below what was modeled, with no roadmap for where the problems actually are.

The lender underwrites debt against an EBITDA that doesn't reflect the full operational picture, and if the leakage continues post-close, debt service coverage tightens and the deal carries more risk than anyone accounted for.

Everyone in the transaction is affected and none of them ever see the gap because the analysis that would have surfaced it was never produced.

Most dental group transactions close on an EBITDA that's lower than the group is actually capable of producing, and nobody involved in the deal ever finds out.

The financial QoE may be clean, with normalized add-backs, verified revenue, and a listing built around a number that's technically financially accurate. But underneath that number, across the locations, there's almost always operational revenue that should be flowing through and isn't. No-show rates running double at certain offices compared to others in the same group, treatment plans that patients accepted a year ago and nobody followed up to schedule, recall systems that quietly stopped functioning after staff turned over and were never rebuilt. That variance adds up to $200K to $500K or more in annual revenue that the group should be producing, and because nobody in the transaction is scoped to evaluate operational performance at the location level, it just sits there suppressing the EBITDA that the entire deal gets priced on.

At 5x to 8x multiples, that's $1M to $3M or more that should have been in the deal and wasn't. The seller goes to market on a number that understates what they built, and the deal closes smaller than the group warranted. Not to mention the broker's commission gets calculated against that smaller number. Nobody did anything wrong. There is simply an entire layer of revenue sitting inside the operations that falls between every discipline involved in the transaction and never gets surfaced.

The part that makes this worth paying attention to is that the revenue isn't theoretical. These are patients already in the system, who already said yes to treatment or were already coming in regularly before someone dropped the process. So recovering it before listing doesn't require projections or assumptions. It requires someone going into the PMS across every location, diagnosing why the variance exists site by site, and building the systems to capture what's there. The EBITDA then goes up on real recovered earnings, the multiple gets applied to a bigger base, and the deal closes at a number that actually reflects the full capability of the group.

The highest leverage move available to dental practices right now isn't more marketing, new tech, adding operatories, or hiring another associate. Current conditions prove it's actually in recovering dormant revenue that's already sitting in the patient base.

Hygienist recruitment has been nearly impossible for three consecutive years and less than half of open positions are actually getting filled. When hygiene staffing is unstable the recall systems fracture, patients fall out of their cycle, follow-up stops happening consistently, and they quietly lapse. This is not a front desk problem but a matter of staffing instability which accumulates in the PMS over months and years without anyone ever formally quantifying what it's costing.

Busyness levels are down and chair availability is up. The capacity to see those lapsed patients is sitting there. So the operational gap and the scheduling gap exist simultaneously but almost nobody is connecting the two. Meanwhile, reimbursement rates aren't keeping pace with supply costs, equipment costs, or wages. Margin pressure is here and isn't going away, which means every dollar recovered from the existing patient base has a higher relative impact than chasing new patient volume through marketing spend. Fees are up too. The average production value per appointment has increased, which means each recovered lapsed patient is worth more than it was a year ago.

Lapsed recall, unscheduled treatment, and no-show patterns represent revenue that exists in the patient base but never converted to a scheduled appointment and never triggered a billing event. It doesn't appear in any financial report because it never became production. It lives in the PMS and it's hiding in plain sight until someone goes looking for it specifically, and systemically, and regularly. Not just seeing the numbers, but actually understanding why they are what they are, diagnosing how to really improve them, and the impact of this all on a deal.

For a practice approaching a transaction, whether to buy or sell, this is the gap between what the trailing financials show and what the practice was actually capable of producing. That gap doesn't disappear at close. It either gets documented and priced in before the deal, or it transfers silently to the buyer as unpriced upside.

Over the past two years, more than 40 DSOs were brought to market in the United States. But fewer than 10 closed. That's a 75% failure rate on platform exits, and the reason is not the financials, it's what the financials never showed.

For the last decade the dental DSO playbook ran on a single bet, that you could buy practices at four to six times EBITDA, roll them into a platform, and exit the platform at 9-14x. The math worked because multiple expansion was already happening, not something you had to necessarily earn. Operational execution at each acquired practice was treated as an integration problem that would sort itself out over time, and financial diligence was treated as sufficient because financial performance was the only thing the next buyer was going to price on.

That entire thesis is breaking right now, and most of the people inside it are still operating like the rules haven't changed.

The market evidence is no longer ambiguous

Lincoln International reported that over the past two years, more than 40 DSOs were brought to market in the United States and fewer than 10 transactions successfully closed. That is roughly a 75% platform exit failure rate, and a recurring theme in the post-mortems is operational reality at the practice level not matching what the platform told its eventual buyer, with the buyer's diligence team finding it, and the deal dying or getting repriced down to a number the seller would not accept.

Becker's Dental Review reported in January 2026 that very few DSOs are now offering more than 65-70% cash at close, with the rest sitting in holdback tied to operational performance post-close. In DSO transactions over the last few years, the percentage of cash at close has been compressing while the percentage held back against post-close performance has been growing. The cash that used to leave the table on closing day is now contingent on whether the practice actually performs the way it was sold to perform, and smaller DSOs are starting to have visible trouble releasing those holdback dollars to sellers a year or two later, which has begun circulating in the broker and seller community in a way that affects how the next deal gets structured.

Industry analysis through 2024 and 2025 consistently shows PE firms holding dental assets for an average of 6 years and longer, well beyond the 3-to-5 year hold model the original thesis was built around. So it's clearly not a matter of market timing, it's becoming a value creation execution problem, and the hold period is where it becomes visible because the operational reality of each tuck-in compounds at the platform level over time. The exit math no longer survives operational surprise.

The pressure stack underneath all of this is structural

Interest rates killed the cheap debt that powered LBO roll-ups. Lenders pulled leverage from around six and a half times EBITDA down closer to five. Entry multiples on tuck-ins crept up from the four-to-five times range into five-to-seven, which compressed the arbitrage from both ends. Hygienist labor shortages have persisted for three consecutive years and now constrain capacity at most multi-location groups. Insurance reimbursement has not kept pace with cost increases. Patients have started deferring elective treatment as economic pressure on households tightens. And the supply of clean acquisition targets has thinned, which has made each remaining good practice harder and more expensive to find.

A roll-up that worked at zero interest rates with abundant labor and easy multiple expansion does not work at 5% debt cost with hygiene staffing shortages and a six-to-eight times exit multiple ceiling. The arbitrage closed. What replaces it is not “no DSOs”, it's strategically operated DSOs. Platforms that actually know which practices to buy, why they are buying them, how to integrate them, and how to extract value from the operations rather than from financial engineering. That tier wins now. Everyone else either quietly recapitalizes, writes down LP capital, or sells at a haircut to whichever strategic acquirer is willing to take on the integration problem.

Underneath all of this is a deeper shift in what the return actually comes from. Because in the old world, the return came from the multiple. You bought at 5x, exited at 12x, and the spread was the return. Operational execution at each tuck-in mattered but did not have to be perfect because the exit multiple absorbed the variance. In the new world, with multiple compression and the exit market broken, the spread is no longer there to absorb anything. The return now has to come from running the specific practice better than the seller did, which means the buyer needs to know exactly where the recoverable upside lives inside that practice before they close the transaction, not after. In a market where multiple expansion no longer delivers the return, the alpha has to come from operations, from running the specific practice better than the seller did. And you cannot capture operational alpha you never documented.

This is the part of the thesis most buyers have not yet absorbed. The price they pay is still set by EBITDA times a multiple, that mechanic hasn't changed, but what has changed is the cost of being wrong about what is underneath that EBITDA. A deal that would have been a lesson learned in 2018 is a fund-economics-damaging miss in 2026. And a deal where the buyer captures upside the seller could not document is the difference between hitting fund targets and missing them.

To put a shape on it: on a typical six-location group, the recoverable operational layer routinely runs into the high six figures of annual production sitting uncaptured in the practice management system. At a 7x multiple, that is over a million dollars of enterprise value that nobody priced, on one tuck-in. Across a platform doing dozens of acquisitions a year, the compounding gap is not a rounding error. It is the difference between a fund that returns and a fund that struggles to raise its next vehicle.

The diligence stack every buyer runs today was built for the old thesis

Financial QoE answers what the practice earned. Organizational diligence addresses people risk. Commercial diligence looks at market position. But none of these answer the topic that matters now, which is what recoverable upside is sitting in the patient base that the trailing financials do not reflect, because none of these were designed to. That answer lives in the PMS data and the patient-level operations that produced those trailing earnings in the first place, and that layer is structurally outside the scope of every existing diligence discipline.

It goes without saying this is not a competence issue. Financial QoE firms know audit and accounting at an institutional level, and they are excellent at what they do. Dental consulting firms know operations and they help practice owners run better practices over months and years of engagement. Brokers facilitate transactions and represent their clients well. Internal operators run the business and know it intimately. Each of those roles is doing exactly what it is set up to do. The gap is what no role is set up to do, which is produce buyer-grade, forensic documentation of the patient-level operational layer in a format that belongs in a deal room and gets used as a transaction input.

Some forms of this work do exist at the edges of the industry, but each has a structural reason it cannot fill the gap.

• Major consulting firms have named full potential diligence as a concept and articulated why it matters, but they are built around six-figure-plus engagements on billion-dollar platform deals and do not run on a two-to-three week post-LOI timeline at lower-middle-market multiples.
• Some of the largest DSO platforms have built internal analytics capability that touches parts of this, but internal dashboards surface the score rather than the forensic diagnosis. The analysis is built post-close rather than delivered as pre-close diligence, and an acquirer's own internal read of a target it is buying carries less weight in the deal room than an independent document, the same reason buyers commission third-party financial QoE rather than relying on their own model.
• Practice management consultants understand the operational layer deeply but produce coaching engagements over months and years, not transaction-grade documentation formatted for a sophisticated buyer's investment committee.
• Some financial QoE firms have begun adding macro-level operational sections to their reports, which is genuinely useful but does not extend to patient-level PMS forensics.

The category of work that does not exist anywhere productized is patient-level operational forensics formatted as a transaction document, deliverable in the post-LOI diligence window, at lower-middle-market and mid-market dental deal economics. That is the specific gap.

The work of documenting that layer therefore does not get done. Buyers underwrite without it, close the acquisition, and discover the true operational picture themselves many months later when their integration team properly opens the PMS and starts pulling reports. Lapsed recall sitting recoverable, unscheduled treatment already accepted at full case value, provider production variance where standardizing the bottom performers to the median moves the EBITDA line, no-show patterns concentrated by location and by chair where capture rate improvements drop straight to margin. All of it has been sitting in the practice management software the entire time, waiting to be captured. But by the time the buyer's team finds it, the integration is already underway, the easy compounding window of months one through six has passed, and what should have been captured upside flowing through the hold period from day one has become a discovery exercise the operating team has to run on top of the business.

The seller leaves the upside on the table, the buyer captures it 12 to 18 months later than they could have, the broker's commission gets calculated against a smaller deal than the group warranted, the lender underwrites against earnings that do not necessarily reflect what the asset is actually capable of producing in the future, and everyone moves on to the next transaction with the same blind spot embedded in the playbook. The cycle repeats on the next deal.

What changes the cycle is a forensic read of the operational layer during diligence, in the window between LOI signature and close, running concurrent with the financial QoE

Not operational diligence in the traditional sense, which evaluates whether the business is well-run at the macro level. The piece of diligence that has been missing is patient-level forensics. It answers:

• What recoverable revenue is sitting in the PMS that never showed up in the trailing financials.
• Which scheduling and treatment-acceptance mechanics are producing the case volume, and which ones are leaving capture rate on the table.
• Where conversion is already happening and where the easy upside lives.
• Which provider variance, when closed, moves the EBITDA line by how much.
• Which patient cohorts have already lapsed and are recoverable, weighted by realistic reactivation probability.
• The exact dollar value of recoverable revenue sitting uncaptured in the practice management system, categorized by leakage type, with the operational root cause behind each category named so the integration team can execute against it from day one.

That picture exists for every practice, it always has. It has just never been extracted, organized, and packaged in a format that holds weight inside a deal room alongside the financial QoE. The data is in the PMS. The methodology to extract it requires forensic technique, deal-room formatting, and benchmark context that no current diligence discipline is structured to produce. Buyers cannot do this work pre-LOI because the seller has not yet granted PMS access. Buyers do not do it post-close because by then the integration is already running and the early-capture window has passed. The only window where the work belongs is post-LOI and pre-close, sitting alongside the financial QoE in the data room.

We named this layer of diligence the Operational Quality of Earnings, because the existing diligence stack did not have a name for it and it deserved one

DRAI was built specifically to produce it.

The deliverable is a transaction document, not a consulting report. It's structured the way a sophisticated buyer's investment committee expects a diligence finding to be structured, with the recoverable revenue quantified by category, the operational mechanic behind each category named and explained, and the recovery pathway described in terms the integration team can execute against from day one of ownership. It runs concurrent with the financial QoE, inside the same diligence window, on the same data room access the buyer already has under the LOI, with no incremental burden on the seller and no timeline impact on the deal. It is reviewed by the buyer's deal team alongside the financial QoE, and the investment committee approves the deal with full visibility into what the practice is actually capable of producing in the future rather than only what the trailing financials suggest.

The price the buyer pays does not necessarily change, what changes is the quality of the bet that price represents. A buyer paying 6x EBITDA on a practice where the recoverable operational upside is documented pre-close is making a different quality of bet than a buyer paying 6x on the same practice where that upside is unknown. Same dollars invested, but one buyer knows exactly what they're buying and the other is essentially making an expensive, risky assumption. The first buyer's integration team captures the upside in months one through six and the EBITDA improvement flows through the hold period from day one. The second buyer's team finds it once the practice is in their reporting stack, typically months after close, and starts capturing it later still, losing the early-compounding window that the new hold-period math cannot afford to lose.

That's why the buyers and platforms who make patient-level operational diligence part of how they underwrite, the ones who bring this analysis into the deal room rather than discovering the gaps after close, will own the next decade of dental PE.

The dental PE category is rewriting its rules right now. Every buyer already knows, in general terms, that operational upside exists inside the practices they acquire. That's not the gap. The gap is that nobody has quantified it at the patient level, in dollars, in a document that sits in the deal room and tells the integration team exactly where the recoverable EBITDA lives and how to capture it from day one.

General awareness is not alpha. Specificity is.

The buyers who bring that specificity into the deal room, rather than discovering it in month twelve, are the ones who come out the other side of this market owning what is left.

DRAI produces the Operational QoE™ for dental transactions: the forensic diagnostic that sits alongside the financial QoE in the data room and quantifies the revenue a practice is leaving uncaptured in its own patient base. We named the category and built the method behind it.

What makes the report defensible is method and independence. Every figure is drawn from the practice's own PMS data, grounded in the staffing and workflows behind the numbers, traced to probable root causes, and converted to EBITDA and deal-multiple impact. We only measure, never fix; the recovery path goes to the client's own team to execute. As a third party with no stake in the outcome, our findings carry weight the parties to a deal cannot manufacture themselves.

At DRAI we're betting that one day, no dental practice will ever again change hands without an independent read on what it can really earn from its existing patient base, the same way no sophisticated deal closes without a financial QoE today.

Is the report templated, or tailored to us?

Both. The method is fixed: the same five categories, the same definitions, the same derivation on every engagement, because that is what makes the figures comparable across locations and defensible to a counterparty. Everything around the method is built to you: the conversion to EBITDA runs on your own cost stack and underwriting targets, the categories are weighted to the deal in front of you, the executive summary is written for the reader you have to convince, and the recovery roadmap is sequenced to your integration calendar. The five categories, your own underwriting targets, and a summary written for your reader are part of every report. Beyond that, where you want something specific examined in the practice management system, a question put to the other side's operations or office management team, or a particular concern of your board, sponsor, or lender worked into the analysis, we add it to the scope wherever it can be done. Where it cannot, we say so before the engagement starts rather than after.

Why doesn't our QoE firm, broker, or consultant already do this?

A financial QoE works from the books: reported earnings, adjusted for owner compensation, personal expenses, and a replacement associate. Every adjustment moves a figure that was billed and collected. What we measure was never billed, because the patient never came back, the plan never got booked, or the appointment never got filled. It is potential production, sitting in the practice management system, and an accounting system cannot record something that did not happen. The most careful earnings bridge will not find it.

Brokers price a listing from the financial package and the seller's account of the practice, which is the right job for a listing. But rebuilding two years of patient behavior from the practice management system is a separate discipline that takes weeks, and it has not been in anyone's scope.

DRAI does not produce financial QoE work. The two reports draw on different data, answer different questions, and sit in the same data room without duplicating a line of each other.

Why has nobody measured this before?

Pieces of it have been. A retention consultant pulls lapsed patients for a practice that hires them. A dashboard shows recall compliance. What has not existed is a single document that measures all five categories, converts them to EBITDA on the buyer's own numbers, and carries a signature from a party with no stake in the deal. Producing that inside a diligence window takes a fixed method, a data request an office manager can complete, and a way of reading every practice management system the same way. Building that took the better part of a year, and nobody in a live deal has a year.

What is the difference between a Portfolio Review and a Pre-Listing engagement?

Same forensics, different document, different clock. A Portfolio Review runs on the locations you intend to keep operating, at any time and usually every year, with no sale in view. It anchors on recurring annual EBITDA, carries no valuation multiple and no date, and its readers are the CFO, the board, and the lender during the hold. A Pre-Listing engagement runs once, 12 to 24 months before a sale, and is aimed at the listing date: it models the trajectory of trailing EBITDA to that date, sequences the capture so the recovery lands in the twelve months a buyer will price, and carries a section built to survive the buyer's own diligence. If you are years from a sale or not planning one, it is the review. If you have a date, it is pre-listing.

Our analytics platform already shows this. What does the report add?

Three things a dashboard is not built to do, whichever side of the deal you are on.

It sees a practice you do not yet own. On an acquisition, the target's practice management system belongs to the seller until close, and its data is not in your reporting stack. DRAI works from the seller's exports inside the diligence window, which is the only way to see the operational opportunity before you commit the capital. After close, bringing the practice into your stack takes months, during which the integration team is on payroll, credentialing, and keeping staff, and the sponsor has already approved the price.

It turns rates into money the deal can use. A dashboard reports a state: recall compliance is 48 percent, or a hundred accepted plans are unscheduled. It does not tell you what that is worth in production, how much of it a competent operator can realistically capture and by when, what survives write-offs and collection rate to reach cash, what that is in EBITDA on your own cost structure, and what that means at your multiple. Getting from the rate to that number takes the practice's own write-off history, a capture rate the practice has already demonstrated, your cost stack, and a method that reconciles every figure against every other. That number is what the board approves capital on, the lender sizes the loan on, and the price is set against, and no dashboard produces it.

It carries a signature the other side will accept. On the sell side, this is the whole point. Your dashboards can show you the opportunity in your own locations. They cannot show a buyer's diligence team anything, because a seller's own reporting is exactly what a buyer discounts. A document produced by a party with no stake in the outcome, with every figure traced to its source and its method written down, is what survives diligence, anchors an earn-out, or explains a recent uplift in trailing earnings before the buyer decides it is a spike. On a portfolio review with no deal in view, the same signature is what the board, the lender, or the next sponsor reads instead of management's account of itself.

Why not build this in-house?

The group's operations people, the CFO, and the deal lead are the readers, each for their own reason, and the report gives each of them the findings to act on. The CEO who uses it well is the one whose team takes the findings and executes.

Inside a DSO this function does not fit the scope of any role. Corporate development runs the deal, FP&A models it, integration inherits it after close, and business intelligence reports on the business day to day. Each is fully employed doing that, and patient-level forensics is a different discipline from all of them. Building the function means hiring someone who understands both dental operations at the patient level and transaction finance, which is a rare combination, carrying that cost permanently against deal volume that arrives in lumps, and then waiting a year for a method to exist, because the definitions, the data request that works across every practice management system, the conversion, and the benchmarks all have to be built and tested before the first number can be defended. That is the same arithmetic that leads acquirers of every size to commission the financial QoE externally rather than staff a QoE team.

“They're good at building systems and processes at the corporate level. But patient-level or practice-level forensics is foreign territory to them. It's not an indictment of those guys, they're really good at what they do. It's patient and practice-level specifics they didn't come up in, so they don't know.”Co-founder of a 50+ location DSO, regarding his COO and VP of Operations

The other reason is the reader. If your own company does this work, your own team is confirming your own thesis, which carries limited weight with a board and none with the next buyer. A third party with nothing to gain from the answer is what makes the number usable in the room.

“I'm less concerned about the cost of outsourcing it. It lends something, credibility might not be the right word, but something that seems more sewn up about a third party providing this.”CEO of a sponsor-backed DSO, on the cost of commissioning it externally

Will this change what we pay, or slow the deal down?

On the buy side, the report is yours and stays private. The opportunity it identifies is not disclosed to the seller, so you are never put in a position of paying for upside that has not been earned yet. Price justification still runs on current earnings, as it always has. Two things can move: if the report finds production concentrated in a provider who may leave, that is quantified as value at risk at your multiple and you can price it, which standard diligence only flags; and if you choose to use the recoverable figure in the deal structure, an earn-out or a holdback for example, every number behind it is derived and shown, so it holds up. If you choose not to, nothing changes about the price, and the difference shows up after close, when the operating plan starts on day one with the opportunities already quantified, instead of after months spent finding them.

On the sell side, the point is the opposite: the report is what lets you put the opportunity in front of the buyer on your terms, documented, before their diligence finds it and uses it against you. Which side holds the information decides who holds the edge, and it is always the side that commissioned the work.

The process runs inside the existing diligence window the financial QoE already takes, on the access the LOI already grants, so it adds no friction to the critical path.

How can we trust the output, and where does AI come in?

Every figure comes from the target's own practice management data. We gather the exports, standardize them, rebuild the patient base's visit and treatment pattern by cohort, and show the source report and the arithmetic behind every number, with the filter recorded so your own advisors can verify any figure against its source.

AI carries the data-heavy work: reading exports from whichever system produced them, rebuilding the visit and treatment pattern by cohort, and checking every figure against every other so the report reconciles in every section. That is how a multi-location group gets the same depth on every location inside four weeks.

Can we see examples of the report before working together?

Yes. The four sample reports are on this site in full. → Sample reports

What does an engagement ask of our team?

One coordinator on your side, usually the VP of operations, the COO, or a regional manager, completes a short group overview form and passes a short location form to each office manager. Each office manager completes that form and exports a fixed set of standard reports from the practice management system through a secure link we provide. That is the whole of it. If anything material cannot be settled from the data, one batched set of written questions goes to the coordinator. We never contact individual offices directly, and nobody on your side needs to clean or prepare anything before sending it; every practice's exports have gaps and inconsistencies, and reconciling them is our work, not yours.

How long does it take, and does it fit inside the post-LOI window?

Four weeks from complete data. On an acquisition that sits inside the post-LOI window, concurrent with the financial QoE, and is delivered before it closes.

How does a referral or partnership work?

Either through you or direct, with a referral arrangement for the advisors who introduce engagements. The mechanics are under Referrals and introductions on the Engagements page.

Who sees the findings?

The party who commissioned them and nobody else. A buyer's findings stay with the buyer. A seller's findings reach the buyer only when the seller chooses to put them in the data room, and that is exactly what a Going to Market engagement is for. No client, partner, or counterparty is named by us in any public or third-party context without their explicit approval.

Do you offer any guarantees?

Every engagement is tailored to your cost stack, your reader, and your calendar before delivery, so the report arrives built for the room it is going into. If, on delivery, you are not satisfied the document is defensible to the other party in your transaction, one revision to that standard is included at no additional fee. Every figure is sourced and shown so your advisors can use it, and every engagement is revisited at 6, 12, and 24 months, at no cost, so you know whether the number held, and every later engagement with you is calibrated on what your own locations actually recovered.

Privacy

DRAI collects the information you submit through this site, such as your name, email address, company, and message, to respond to your enquiry and to administer engagements. We do not sell personal information. We do not collect or process patient-identifiable data on any engagement. Requests to access or delete information you have provided can be made through the contact form or by contacting us directly.

Terms

The content of this site is provided for general information. It does not constitute legal, tax, accounting, or investment advice and does not create an engagement or an advisory relationship. Engagements are governed solely by a signed engagement letter.

Disclosures

The Operational Quality of Earnings is an operational analysis of practice management system data. It is not an audit, a financial quality of earnings, or a valuation, and it does not propose transaction terms. Figures presented on this site are illustrative. DRAI is commissioned by one side of a transaction only,does not name clients, partners, or counterparties in any public context unless written or verbal permission has been explicitly given.